BioPharmX names new chief operating officer
17 July 2019 -

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced yesterday that it has named Steven M Bosacki as its new chief operating officer.

Bosacki earlier served as senior vice president and general counsel under BioPharmX CEO, Dr David S Tierney, at Oceana Therapeutics. Earlier, he served as president and CEO of Lautus Pharmaceuticals.

In his newly appointed role at BioPharmX, Bosacki will manage all operational aspects of the business including clinical, regulatory, pharmaceutical development and legal activities.